Redeye updates its estimates and valuation following Cheffelo’s Q3 2025 report.
Redeye considers Arise’s Q3 2025 report to be largely in line with estimates when adjusting for one-...
* Reports Q3 in line with pre-announced figures * Seasonally weaker quarter, but 17% organic growth ...
Redeye’s analyst just published a Research Update on Devyser Diagnostics.
Redeye is positive to GomSpace’s trading update published this morning, which posted solid financial...
Redeye provides an initial take on Kontigo Care’s Q3 2025 results.
Redeye provides its initial take on Acarix’s Q3 report, which showed record quarterly sales driven b...
Redeye provides its first take on Camurus’ Q3 report 2025, published this morning.
CapMan’s Q3 fee income of EUR 15.2m grew 19% y/y and was slightly ahead with our estimate of EUR 14.
Redeye updates on G5 Entertainment following Q3 results, which were softer than expected due to high...
Redeye provides an update following Neola Medical’s Q3 2025 report.
Redeye returns with smaller near-term forecast adjustments following a Q3'25 report that was largely...
* Solid top-line and earnings growth, but elevated churn * We lower '25e-'26e adj.
* Q3 soft, lower volumes from two major customers * We cut '26e-'27e sales and EBIT by 6% and SEK 6m...
* Pre-announced sales down 28% y-o-y due to several headwinds * 5m EE milestone pushed to '27 due to...
Redeye remains confident on the case as we see solid prospects for continued rapid growth and good o...
Administer's Q3 results fell short of expectations as net sales declined to EUR 17.
Redeye considers Bredband2’s Q3 report to be largely in line with estimates, posting growth of 9% y/...
* Q3 sales SEK 22m (-22% y-o-y), EBIT -6.4m (vs. ABGSCe -4.
* Sales in line but adj. EBIT 31% below consensus..
